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Despite many global initiatives and efforts to improve the availability of 
marketing authorized dosage forms appropriate for pediatric population, there is still 
a supportive evidence  and widespread need for the implementation of the concept 
of unlicensed (UL) and “off-label” (OL) medicines use as a common therapeutic 
strategy or as the only treatment option and standard of health care for this 
vulnerable population. As acknowledge, prescription, compounding, dispensing and 
administration of UL and OL use of medicines should be regulated within the 
national profile of health care policy. Bearing in mind that in our country there is no 
formal mechanism for management of OL drug prescribing and use that could lead 
to their quality use, this concept continues to be an important public health issue. 
For this underlining reason the purpose of our survey is to present the best practices 
and risk assessment strategy for UL and OU of medicines in pediatric population. 
First of all it is of paramount importance to establish national policies governing UL 
and OL prescribing and use along with ethical standard since prescribing by clinicians 
is an area of practice that is not regulated by drug regulatory authorities. Strategies 
for collaboration and the shared responsibilities among prescribers, clinicians, 
pharmacists and regulators with regard to the OL and UL medicines use should be 
developed and adopted on every level of pediatric health care. The process of 
determining the need for UL and OL medicines for pediatric population will serve for
regulation of certain uses. Responsible OL and UL prescribing also require 
development of explicit guidance for pediatric clinicians to assess appropriateness, to 
evaluate safety and efficacy of OL and UL prescribing justified by high-quality 
evidence as well as in the cases where adequate evidence is lacking. Moreover, 
monitoring system for OL and UL medicines use by indication then, active collection 
of safety data and systematically monitoring of pediatric patient responses to OL use 
will decrease and prevent risky and ineffective OL prescribing. There is a need of 
policy reforms to promote care giver and public interest in evidence-based OL 
prescribing. Another issue that has to be regulated is the potential cost associated 
with this concept of use of medicines in paediatric drug therapy.
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strategy or as the only treatment option and standard of health care for this 
vulnerable population. As acknowledge, prescription, compounding, dispensing and
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and OL prescribing and use along with ethical standard since prescribing by clinicians
is an area of practice that is not regulated by drug regulatory authorities. Strategies 
for collaboration and the shared responsibilities among prescribers, clinicians, 
pharmacists and regulators with regard to the OL and UL medicines use should be
developed and adopted on every level of pediatric health care. The process of 
determining the need for UL and OL medicines for pediatric population will serve for
regulation of certain uses. Responsible OL and UL prescribing also require
development of explicit guidance for pediatric clinicians to assess appropriateness, to
evaluate safety and efficacy of OL and UL prescribing justified by high-quality 
evidence as well as in the cases where adequate evidence is lacking. Moreover,
monitoring system for OL and UL medicines use by indication then, active collection 
of safety data and systematically monitoring of pediatric patient responses to OL use 
will decrease and prevent risky and ineffective OL prescribing. There is a need of
policy reforms to promote care giver and public interest in evidence-based OL 
prescribing. Another issue that has to be regulated is the potential cost associated
with this concept of use of medicines in paediatric drug therapy.
